Spark Ventures
VC Fund
London, United Kingdom
Spark Ventures is a VC fund in London focused on Software and Biotechnology. SPARK Ventures, formerly NewMediaSpark, is an early-stage venture capital investor in Europe, providing equity investment to high growth technology, media and healthcare companies in the UK and Europe. SPARK Ventures has been investing in early-stage businesses for 12 years and has a wealth of expertise in backing and developing companiesfrom start-up through to eventual trade sale or IPO.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 20%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Spark Ventures invests in
Stages Spark Ventures invests in
Countries Spark Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Series A
- $1.5M–$14M
- Series B
- $2.9M–$16M
Investment Focus
Industry
- Software 6 (24%)
- Biotechnology 4 (16%)
- Medical 3 (12%)
- Hardware 3 (12%)
- Education 3 (12%)
Stage
- Funding Round 7 (28%)
- Series B 5 (20%)
- Series A 3 (12%)
- Seed 2 (8%)
- Venture - Series Unknown 2 (8%)
Country
- United Kingdom 14 (56%)
- United States 2 (8%)
- China 1 (4%)
- India 1 (4%)
- Australia 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kiko Duffy
Founder and Investment Director
|
Founder and Investment Director | Total investments: 1 | Find email | |
Thomas Teichman
Chairman and Executive Director
|
Chairman and Executive Director | Total investments: 6 | Find email | |
Andy Betton
Financial Director
|
Financial Director | Total investments: 0 | Find email | |
Jonathan Gee
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
Martin Williams
Director
|
Director | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Unmarshal is a Decentralized network of blockchain data indexers and transforming tools to power DeFi applications on any chain. | $2.6M / Seed / Mar 19, 2021 | ||
|
Study119.com
|
Study119.com is a professional firefighter education and training service platform. | $1.5M / Seed / Jan 25, 2019 | |
| MyOffer is a Shenzhen-based online overseas study application platform. It provides information on over one million courses available at universities around the world. The company plans to expand its business in the field of visa application, accommodation, careers planning, overseas experience, and employment for overseas students. | $2.9M / Series B / Dec 19, 2018 | ||
| Simba Sleep is an e-commerce company that offers a variety of mattresses. It brings together thousands of super-light comfort springs and support from precision-engineered foam in perfect harmony.The company is driven by a mission is to bring the importance of sleep back into focus, and help everyone wake up winning. Simba Sleep was founded in2015 and is headquartered in London, England. | $6.1M / Venture - Series Unknown / Oct 13, 2016 | ||
| Simba Sleep is an e-commerce company that offers a variety of mattresses. It brings together thousands of super-light comfort springs and support from precision-engineered foam in perfect harmony.The company is driven by a mission is to bring the importance of sleep back into focus, and help everyone wake up winning. Simba Sleep was founded in2015 and is headquartered in London, England. | $1.5M / Series A / Feb 10, 2016 | ||
| Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. | $13M / Venture - Series Unknown / Feb 01, 2014 | ||
| Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation ofclots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients. | $2.9M / Nov 02, 2012 | ||
| Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed toreplace the century old Mantoux skin test ( TST ). | $28M / Jun 18, 2012 | ||
| Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locatetheir strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996. | $842K / May 08, 2012 | ||
| Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation ofclots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients. | Series C / Aug 01, 2011 | ||
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Spark Ventures invest in?
Spark Ventures invests primarily in Software, Biotechnology and Medical startups, most often at Funding Round and Series B stage. Most of the 25 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Spark Ventures's check size?
Spark Ventures typically joins rounds of $1.5M–$14M at Series A and $2.9M–$16M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Spark Ventures participates in.
How do I contact Spark Ventures?
Public channels for Spark Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Spark Ventures?
The team at Spark Ventures includes Kiko Duffy (Founder and Investment Director), Thomas Teichman (Chairman and Executive Director) and Andy Betton (Financial Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
